Mavacamten Improves Health Status in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
NEJM Journal Watch（2021）
摘要
In the industry-funded, randomized, controlled EXPLORER-HCM trial, mavacamten, a non–FDA-approved selective cardiac myosin inhibitor, improved peak
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要